ALK and non-small cell lung carcinoma: A post-hoc analysis of the J-ALEX study by Nishio et al., which included ALK+ NSCLC patients who were untreated or with at most one prior chemotherapy regimen, demonstrated that alectinib reduced the risk of CNS progression by approximately 50% and 20% in patients with and without baseline BM, respectively (82).